A Blowout Call on Biotech Select
I have two simple goals with this brief missive: Give well-deserved kudos to Adam Feuerstein for his call on CV Therapeutics (CVTX) that he recently added to the portfolio of Biotech Select, a premium service from TheStreet.com. And second, if you're interested in biotech stocks, you should subscribe to Biotech Select.
Adam added CV Therapeutics to the model portfolio of Biotech Select on Jan. 20, when the stock was trading at $10.75 a share. Shares of CVTX rose to $16.68 in intraday trading today on news that the company had received and rejected a $16-per-share takeover offer from Japanese drugmaker Astellas.
Subscribers of Biotech Select who followed Feuerstein's buy suggestion gained more than 50% from this position in just five trading days!
Nice work, Adam. Click here to take a free trial to Biotech Select and receive all of Adam's commentary and stock recommendations.
Let's stay interactive. Dave Morrow Editor-in-ChiefSelect the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
